{"id":"NCT02607865","sponsor":"Novo Nordisk A/S","briefTitle":"Efficacy and Long-term Safety of Oral Semaglutide Versus Sitagliptin in Subjects With Type 2 Diabetes","officialTitle":"Efficacy and Long-term Safety of Oral Semaglutide Versus Sitagliptin in Subjects With Type 2 Diabetes","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-02-15","primaryCompletion":"2017-02-14","completion":"2018-03-28","firstPosted":"2015-11-18","resultsPosted":"2020-02-27","lastUpdate":"2022-07-20"},"enrollment":1864,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Diabetes","Diabetes Mellitus, Type 2"],"interventions":[{"type":"DRUG","name":"semaglutide","otherNames":[]},{"type":"DRUG","name":"sitagliptin","otherNames":[]},{"type":"DRUG","name":"placebo","otherNames":[]}],"arms":[{"label":"Semaglutide 3 mg","type":"EXPERIMENTAL"},{"label":"Semaglutide 7 mg","type":"EXPERIMENTAL"},{"label":"Semaglutide 14 mg","type":"EXPERIMENTAL"},{"label":"Sitagliptin 100 mg","type":"ACTIVE_COMPARATOR"}],"summary":"This trial is conducted globally. The aim of the trial is to investigate efficacy and long-term safety of oral semaglutide versus sitagliptin in subjects with type 2 diabetes.","primaryOutcome":{"measure":"Change in HbA1c: Week 26","timeFrame":"Week 0, week 26","effectByArm":[{"arm":"Oral Semaglutide 3 mg","deltaMin":-0.6,"sd":1},{"arm":"Oral Semaglutide 7 mg","deltaMin":-1.1,"sd":1.1},{"arm":"Oral Semaglutide 14 mg","deltaMin":-1.3,"sd":1},{"arm":"Sitagliptin 100 mg","deltaMin":-0.8,"sd":0.9}],"pValues":[{"comp":"OG002 vs OG003","p":"< 0.0001"},{"comp":"OG002 vs OG003","p":"< 0.0001"},{"comp":"OG001 vs OG003","p":"< 0.0001"},{"comp":"OG001 vs OG003","p":"< 0.0001"},{"comp":"OG000 vs OG003","p":"= 0.0856"},{"comp":"OG000 vs OG003","p":"= 0.0080"},{"comp":"OG002 vs OG003","p":"<0.0001"},{"comp":"OG002 vs OG003","p":"<0.0001"},{"comp":"OG001 vs OG003","p":"<0.0001"},{"comp":"OG001 vs OG003","p":"<0.0001"},{"comp":"OG000 vs OG003","p":"=0.3851"},{"comp":"OG000 vs OG003","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":9},"locations":{"siteCount":242,"countries":["United States","Argentina","Brazil","France","Germany","India","Israel","Japan","Mexico","Romania","Russia","South Africa","Turkey (TÃ¼rkiye)","Ukraine","United Kingdom"]},"refs":{"pmids":["30903796","34472698","35064550","35373893","37178435","33660198","32998732","32267058","31903692"],"seeAlso":["http://novonordisk-trials.com"]},"adverseEventsSummary":{"seriousAny":{"events":64,"n":466},"commonTop":["Nausea","Nasopharyngitis","Diarrhoea","Headache","Upper respiratory tract infection"]}}